ACTIV Virtual Biorepository
Through its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, NIH has launched a suite of adaptive master protocol-driven clinal trials that have tested prioritized therapeutic candidates, including immune modulators, monoclonal antibodies, antithrombotics, and other therapies. These trials have generated biospecimens that could be critical research resources for further studies elucidating the pathobiology of COVID-19 and potentially identifying therapeutic targets.
While biospecimens are currently stored by each ACTIV study biorepository, this central web-based virtual biorepository portal provides a readily searchable systematic inventory of the samples and associated meta-data as well as the ability to apply for access to these biospecimens.
To request access to the virtual biorepository, please email activ-biorep@rti.org.
Trial Overviews
| Trial | Description | Specimen Availability | Treatments |
|---|---|---|---|
| ACTIV1: Immune Modulators | Investigated immune modulators compounds to minimize the deleterious effects of an overactive immune response to SARS-CoV-2 infection. | Available |
Abatacept (Orencia) and Remdesivir, Cenicriviroc (CVC) and Remdesivir, Infliximab (Remicade) and Remdesivir, Matching Placebo and Remdesivir |
| ACTIV2: Outpatient Monoclonal Antibodies and Other Therapies | Investigated interventions to reduce the duration of symptoms and increase the proportion of participants with undetectable virus. | Pending | |
| ACTIV3: Inpatient Monoclonal Antibodies and Other Therapies | Investigated interventions to reduce time to recovery and improve recovery including reducing effects on extrapulmonary complications and respiratory dysfunction. | Not Available | |
| ACTIV4: Antithrombotics and Other Therapies | Investigated interventions to reduce time to recovery and improve recovery including preventing clotting events. | Available |
ACTIV4a: Crizanlizumab, Heparin, P2Y12 Inhibitor, SGLT2i Inhibitor ACTIV4c: Apixaban, Placebo ACTIV4d: Fostamatinib, TRV027, TXA127, Placebo |
| ACTIV5: Big Effect Trial | Investigated interventions to improve outcomes in hospitalized adults. | To Be Determined | |
| ACTIV6: Outpatient Repurposed Drugs | Investigated repurposed interventions reduce duration of severity of symptoms. | Not Available |